Estudios originales
Published on 21 de julio de 2025 | http://doi.org/10.5867/medwave.2025.06.3002
Thrombotic thrombocytopenic purpura: Description and analysis of 23 cases treated in Chile between 2017 and 2022
Back to article
Proposed clinical outcomes in PTT.
| Clinical remission | Sustained clinical response after discontinuation of PEX for at least 30 days. It is usually associated at least with a stabilization of the organic damage produced by the disease. |
| Laboratory | ADAMTS13 demonstration ≥ 20%. May be considered partial (≥ 20% but less than LSN) or total (> LSN) remission. |
| Exacerbation | Platelet count below 150,000 (excluding other causes of thrombocytopenia), within 30 days of clinical response (i.e. before achieving remission criteria), with or without evidence of new organ damage. |
| Clinical | There is a drop in platelet count below 150,000, regardless of whether organ damage is present, after achieving remission, whether clinical or laboratory. |
| Laboratory | Drop in ADAMTS13 activity below 20%, after having achieved remission, either clinical or laboratory. |
| Refractory disease | Persistent thrombocytopenia < 50 000 or lack of sustained increase in platelet count, with LDH > 1.5 times the LSN, despite 5 PEX and corticosteroid treatment. In addition, it is defined as severe if platelets are < 30 000. |
LDH, lactate dehydrogenase; PEX, plasma exchange. TTP, thrombotic thrombocytopenic purpura.UNL, upper normal limit.
Links currently accepted in the literature.
Source: adapted from Scully et. al [10].